AstraZeneca has reported a double win after the FDA approved its Imfinzi for a form of lung cancer, and it stopped a trial of its Farxiga after showing “overwhelming efficacy” in chronic ki
Paul Tunnah sat down with AstraZeneca's vice president of sustainability strategy and engagement Jim Massey to discuss how the global pharma company is embracing a green future.
AstraZeneca has announced a collaboration with UK biotech Silence Therapeutics to develop gene silencing drugs for cardiovascular, renal, metabolic and respiratory diseases.
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.